GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (OTCPK:SNBIF) » Definitions » Net Income

SanBio Co (SanBio Co) Net Income : $-18.77 Mil (TTM As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. SanBio Co's Net Income for the three months ended in Jan. 2024 was $-5.20 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jan. 2024 was $-18.77 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. SanBio Co's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was $-0.08.


SanBio Co Net Income Historical Data

The historical data trend for SanBio Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Net Income Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.20 -32.62 -40.74 -42.62 -18.08

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.14 -4.69 -8.24 -0.64 -5.20

SanBio Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

SanBio Co's Net Income for the fiscal year that ended in Jan. 2024 is calculated as

Net Income(A: Jan. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-17.377+-0.699+0+0.0010000000000012
=-18.08

SanBio Co's Net Income for the quarter that ended in Jan. 2024 is calculated as

Net Income(Q: Jan. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-5.469+0.265+0+8.8817841970013E-16
=-5.20

Net Income for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co  (OTCPK:SNBIF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

SanBio Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


SanBio Co Net Income Related Terms

Thank you for viewing the detailed overview of SanBio Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (SanBio Co) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (SanBio Co) Headlines

From GuruFocus

Q2 2019 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2024 SanBio Co Ltd Earnings Presentation Transcript

By GuruFocus Research 02-15-2024

Q2 2022 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2021 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2023 SanBio Co Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024